Speed Of Novel Approvals In Jeopardy As RFK Jr. Lands US HHS Secretary Nod

The FDA’s Peter Marks warned novel approvals will suffer if the agency is forced to spend its time relitigating vaccines. At the top HHS post Kennedy could impact pharma from basic research funding to drug pricing.

Robert F. Kennedy Jr.
President-elect Trump announced 14 November his intent to nominate RFK Jr. to lead the Health and Human Services Department. (Juli Hansen/Shutterstock.com)

President-elect Donald Trump announced his intent to nominate Robert F. Kennedy Jr. to lead the US Health and Human Services Department on 14 November, just one day after one of the US Food and Drug Administration’s top regulators warned the agency’s ability to approve innovative treatments could suffer under the leadership of an anti-vaccine activist like Kennedy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Pathways & Standards